Real-World Experience Using Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis From a Single Outpatient Dermatology Clinic

被引：3
作者：
Cirone, Katrina D. [1 ]
Lovegrove, Fiona E. [1 ,2 ,3 ]
机构：
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Lovegrove Dermatol, London, ON, Canada
[3] Lovegrove Dermatol, 207-140 Oxford St East, London, ON, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2024年 / 28卷 / 01期
关键词：
bimekizumab; psoriasis; biological therapy; real-world data; systemic therapy; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY;
D O I：
10.1177/12034754231217205
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
[41]   Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study [J].
Ding, Yangfeng ;
Li, Wei ;
Guan, Xin ;
Liu, Na ;
Zhou, Ying ;
Li, Gaojie ;
Wang, Xiaohua ;
Wang, Zhidong ;
Xiao, Xiao ;
Yang, Bin ;
Lv, Chengzhi ;
Zhang, Chunlei ;
Shi, Yuling .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10) :1803-1814
[42]   Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience [J].
Diotallevi, Federico ;
Campanati, Anna ;
Radi, Giulia ;
Molinelli, Elisa ;
Offidani, Annamaria .
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (06) :739-743
[43]   Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry [J].
Kojanova, Martina ;
Turkova, Barbora ;
Gkalpakiotis, Spyridon ;
Cetkovska, Petra ;
Fialova, Jorga ;
Dolezal, Tomas ;
Machovcova, Alena ;
Apol, Eydna Didriksen .
ADVANCES IN THERAPY, 2024, 41 (10) :3951-3971
[44]   Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT) [J].
Drach, Mathias ;
Papageorgiou, Karolina ;
Maul, Julia-Tatjana ;
Djamei, Vahid ;
Yawalkar, Nikhil ;
Hausermann, Peter ;
Anzengruber, Florian ;
Navarini, Alexander A. .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2019, 311 (10) :753-760
[45]   Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center [J].
Jung, Seung-Won ;
Lim, Sung Ha ;
Jeon, Jae Joon ;
Heo, Yeon-Woo ;
Choi, Mi Soo ;
Hong, Seung-Phil .
BIOMEDICINES, 2022, 10 (05)
[46]   Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year [J].
Galluzzo, Marco ;
Talamonti, Marina ;
Bernardini, Nicoletta ;
Chiricozzi, Andrea ;
De Simone, Clara ;
Bonifati, Claudio ;
Bruni, Pierluigi ;
Diotallevi, Federico ;
Esposito, Maria ;
Graceffa, Dario ;
Hansel, Katharina ;
Loconsole, Francesco ;
Moretta, Gaia ;
Mugheddu, Cristina ;
Papini, Manuela ;
Richetta, Antonio ;
Skroza, Nevena ;
Atzori, Laura ;
Fargnoli, Maria Concetta ;
Persechino, Severino ;
Offidani, Annamaria ;
Stingeni, Luca ;
Peris, Ketty ;
Potenza, Concetta ;
Bianchi, Luca .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) :1585-1592
[47]   Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice [J].
Herrera-Acosta, Enrique ;
Garriga-Martina, Gustavo Guillermo ;
Suarez-Perez, Jorge Alonso ;
Martinez-Garcia, Eliseo ;
Herrera-Ceballos, Enrique .
DERMATOLOGIC THERAPY, 2020, 33 (06)
[48]   A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis [J].
Napolitano, Maddalena ;
Fabbrocini, Gabriella ;
Potestio, Luca ;
Fontanella, Giuseppina ;
Picone, Vincenzo ;
Bennardo, Luigi ;
Scalvenzi, Massimiliano ;
Patruno, Cataldo .
DERMATOLOGIC THERAPY, 2022, 35 (08)
[49]   An 11-year single centre experience with etanercept use in the treatment of moderate-to-severe psoriasis: a retrospective report [J].
Lim, C. E. ;
Oon, H. H. ;
Chong, W. S. .
HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2019, 27 (04) :165-169
[50]   Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) [J].
Girolomoni, Giampiero ;
Feldman, Steven R. ;
Egeberg, Alexander ;
Puig, Luis ;
Jung, Jinah ;
Jung, Hojung ;
Lee, Younju .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
12345